

# Valentina Gianfelici

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772847/publications.pdf>

Version: 2024-02-01

29  
papers

1,322  
citations

430754

18  
h-index

501076

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 186-190.	9.4	365
2	JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. <i>Blood</i> , 2014, 124, 3092-3100.	0.6	128
3	Identification of a novel, recurrent <i>MBTD1-Xorf67</i> fusion in low-grade endometrial stromal sarcoma. <i>International Journal of Cancer</i> , 2014, 134, 1112-1122.	2.3	117
4	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997.	1.5	110
5	Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 4476-4479.	0.6	96
6	High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes. <i>PLoS ONE</i> , 2012, 7, e38463.	1.1	58
7	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
8	Rapid identification of <i>BCR-ABL1</i> -like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018, 181, 642-652.	1.2	46
9	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	1.7	44
10	Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e314-e322.	1.8	28
11	Activation of the NOTCH1 pathway in chronic lymphocytic leukemia. <i>Haematologica</i> , 2012, 97, 328-330.	1.7	27
12	DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 64-66.	1.7	27
13	Biological Aspects of mTOR in Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2396.	1.8	24
14	Genomic Characterization of Acute Leukemias. <i>Medical Principles and Practice</i> , 2014, 23, 487-506.	1.1	23
15	Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts. <i>British Journal of Haematology</i> , 2017, 178, 583-587.	1.2	23
16	Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e314-e322.	1.8	23
17	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	0.8	20
18	High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. <i>Leukemia</i> , 2018, 32, 1807-1810.	3.3	20

#	ARTICLE	IF	CITATIONS
19	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 951-958.	1.7	18
20	Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia. <i>Journal of Medical Virology</i> , 2010, 82, 1201-1207.	2.5	13
21	Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 25-35.	1.0	12
22	Chromosomal aberrations and fusion genes in myeloid malignancies. <i>Expert Review of Hematology</i> , 2012, 5, 381-393.	1.0	11
23	<i>IL7R</i> overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. <i>Leukemia and Lymphoma</i> , 2019, 60, 829-832.	0.6	10
24	A case of lineage switch from B-cell acute lymphoblastic leukaemia to acute myeloid leukaemia. Role of subclonal/clonal gene mutations. <i>British Journal of Haematology</i> , 2016, 174, 648-651.	1.2	7
25	A novel point mutation within the juxtamembrane domain of the <i>flt3</i> gene in acute myeloid leukemia. <i>Annals of Hematology</i> , 2011, 90, 845-846.	0.8	6
26	FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. <i>Leukemia Research</i> , 2012, 36, 37-41.	0.4	5
27	CD45 antigen negativity in T-lineage ALL correlates with <i>PTPRC</i> mutation and sensitivity to a selective JAK inhibitor. <i>British Journal of Haematology</i> , 2015, 171, 884-887.	1.2	4
28	Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 268-271.	1.3	3
29	Molecular Monitoring of Acute Myeloid Leukemia Patients Carrying Nucleophosmin (NPM1) Mutations Undergoing An Autologous Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 4864-4864.	0.6	0